ADAM9 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant ADAM9.
|Application ||WB, E|
|Calculated MW||90556 Da|
|Other Names||Disintegrin and metalloproteinase domain-containing protein 9, ADAM 9, 3424-, Cellular disintegrin-related protein, Meltrin-gamma, Metalloprotease/disintegrin/cysteine-rich protein 9, Myeloma cell metalloproteinase, ADAM9, KIAA0021, MCMP, MDC9, MLTNG|
|Target/Specificity||ADAM9 (NP_003807, 36 a.a. ~ 135 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||ADAM9 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The protein encoded by this gene interacts with SH3 domain-containing proteins, binds mitotic arrest deficient 2 beta protein, and is also involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. Several alternatively spliced transcript variants have been identified for this gene.
RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells. Xu Q, et al. Tumour Biol, 2010 Jun. PMID 20422344.Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: implications for tumor progression and prognosis. Tao K, et al. Jpn J Clin Oncol, 2010 Jul. PMID 20388695.Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. Taylor DR, et al. J Biol Chem, 2009 Aug 21. PMID 19564338.Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. I?eri OD, et al. Cancer Chemother Pharmacol, 2010 Feb. PMID 19543729.Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions. Cominetti MR, et al. Biochimie, 2009 Aug. PMID 19505527.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.